J. W. Vardiman

4.4k total citations · 2 hit papers
37 papers, 3.2k citations indexed

About

J. W. Vardiman is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, J. W. Vardiman has authored 37 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 18 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in J. W. Vardiman's work include Chronic Lymphocytic Leukemia Research (13 papers), Acute Myeloid Leukemia Research (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). J. W. Vardiman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Acute Myeloid Leukemia Research (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). J. W. Vardiman collaborates with scholars based in United States, Germany and United Kingdom. J. W. Vardiman's co-authors include Ayalew Tefferi, Georges Flandrin, Hans Konrad Müller‐Hermelink, Elaine S. Jaffe, J Diébold, Nancy L. Harris, T. Lister, C. D. Bloomfield, HM Golomb and John Anastasi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. W. Vardiman

37 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

2007 669 citations Ayalew Tefferi, J. W. Vardiman Leukemia profile →
The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1999 649 citations Nancy L. Harris, Elaine S. Jaffe et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. W. Vardiman United States	20	1.7k	1.2k	1.2k	805	778	37	3.2k
Richard Garand France	32	1.5k 0.9×	1.1k 0.9×	1.5k 1.2×	957 1.2×	917 1.2×	80	3.2k
Stefano Sacchi Italy	30	888 0.5×	1.0k 0.9×	843 0.7×	693 0.9×	999 1.3×	145	2.8k
A. Georgii Germany	30	1.4k 0.8×	616 0.5×	1.3k 1.1×	575 0.7×	516 0.7×	115	2.9k
Diane C. Arthur United States	33	1.1k 0.7×	895 0.7×	2.0k 1.7×	1.0k 1.3×	858 1.1×	78	4.1k
Vito Franco Italy	23	1.2k 0.7×	937 0.8×	727 0.6×	522 0.6×	576 0.7×	70	2.5k
J C Brouet France	28	725 0.4×	553 0.5×	992 0.8×	684 0.8×	626 0.8×	70	2.9k
Juan Luis Garcı́a Spain	29	836 0.5×	806 0.7×	1.2k 1.0×	1.3k 1.6×	984 1.3×	127	3.2k
Bridget S. Wilkins United Kingdom	26	2.5k 1.5×	841 0.7×	1.6k 1.3×	1.6k 2.0×	513 0.7×	81	4.2k
Cesare Guglielmi Italy	24	1.3k 0.7×	2.3k 1.9×	1.4k 1.1×	463 0.6×	1.8k 2.3×	67	3.9k
Yang O. Huh United States	35	1.6k 0.9×	1.3k 1.0×	2.4k 2.0×	664 0.8×	1.2k 1.5×	104	4.7k

Countries citing papers authored by J. W. Vardiman

Since Specialization

Citations

This map shows the geographic impact of J. W. Vardiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. W. Vardiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. W. Vardiman more than expected).

Fields of papers citing papers by J. W. Vardiman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. W. Vardiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. W. Vardiman. The network helps show where J. W. Vardiman may publish in the future.

Co-authorship network of co-authors of J. W. Vardiman

This figure shows the co-authorship network connecting the top 25 collaborators of J. W. Vardiman. A scholar is included among the top collaborators of J. W. Vardiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. W. Vardiman. J. W. Vardiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Jason X., John Anastasi, Erica L. Kleinbrink, et al.. (2013). Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. Leukemia. 27(6). 1291–1300. 10 indexed citations

Mesa, Ruben A., Anthony R. Green, Giovanni Barosi, et al.. (2010). MPN-associated myelofibrosis (MPN-MF). Leukemia Research. 35(1). 12–13. 33 indexed citations

Tefferi, Ayalew & J. W. Vardiman. (2007). Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 22(1). 14–22. 669 indexed citations breakdown →

Thiele, J., Hans Michael Kvasnicka, & J. W. Vardiman. (2006). Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl. Best Practice & Research Clinical Haematology. 19(3). 413–437. 30 indexed citations

Thiele, J., H. M. Kvasnicka, J. W. Vardiman, et al.. (2004). Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Annals of Hematology. 83(8). 513–21. 12 indexed citations

Byrd, John C., B. Peterson, Lawrence D. Piro, et al.. (2003). A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 17(2). 323–327. 41 indexed citations

Vardiman, J. W.. (2001). Myelodysplastic Syndrome: Myelodysplastic Syndrome Associated with Isolated del(5q)Chromosome Abnormality ('5q- Syndrome'). 2001(1205). 100197–100197. 2 indexed citations

Diebold, Joachim, et al.. (2000). THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES REPORT OF THE CLINICAL ADVISORY COMMITTEE MEETING. Journal of Clinical Oncology. 13. 193–207. 167 indexed citations

Harris, Nancy L., Elaine S. Jaffe, J Diébold, et al.. (2000). The World Health Organization Classification of Neoplasms of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting – Airlie House, Virginia, November, 1997. The Hematology Journal. 1(1). 53–66. 240 indexed citations

10.

Harris, Nancy L., Elaine S. Jaffe, J Diébold, et al.. (2000). Lymphoma classification – from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. Annals of Oncology. 11. S3–S10. 261 indexed citations

11.

Harris, Nancy L., Elaine S. Jaffe, J Diébold, et al.. (1999). The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. Annals of Oncology. 10(12). 1419–1432. 649 indexed citations breakdown →

12.

Anastasi, John, et al.. (1998). Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive. Leukemia. 12(2). 233–237. 11 indexed citations

13.

Dickstein, Jerome I. & J. W. Vardiman. (1995). Hematopathologic findings in the myeloproliferative disorders.. PubMed. 22(4). 355–73. 46 indexed citations

14.

Hruban, Z., et al.. (1992). Haematopoietic malignancies in zoo animals. Journal of Comparative Pathology. 106(1). 15–24. 42 indexed citations

15.

Golomb, Harvey M., A Fefer, David W. Golde, et al.. (1991). Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B. Leukemia & lymphoma. 4(2). 99–102. 10 indexed citations

16.

Ratain, Mark J., Harvey M. Golomb, J. W. Vardiman, et al.. (1988). Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.. Journal of Clinical Oncology. 6(11). 1714–1721. 60 indexed citations

17.

Golomb, Harvey M., Mark J. Ratain, A Fefer, et al.. (1988). Randomized Study of the Duration of Treatment With Interferon Alfa-2B in Patients With Hairy Cell Leukemia. JNCI Journal of the National Cancer Institute. 80(5). 369–373. 48 indexed citations

18.

Bitter, MA, et al.. (1988). Hairy-cell leukemia. Morphologic, cytochemical, and immunologic features.. PubMed. 8(1). 179–95. 14 indexed citations

19.

Bitter, MA, et al.. (1988). Hairy-Cell Leukemia. Clinics in Laboratory Medicine. 8(1). 179–195. 8 indexed citations

20.

Check, Irene J., Robert L. Hunter, Theodore Karrison, et al.. (1981). Prognostic significance of immunological tests in lung cancer.. PubMed. 43(2). 362–9. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact